ChronoScale (CHRN) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was $3.4 million, down 10% year-over-year, mainly due to lower average selling prices and decreased legacy and EVO device sales, partially offset by higher Personal Health device shipments.

• Gross margin improved to 54% from 52% in Q1 2024, driven by supply chain cost savings and reduced service costs.

• Net loss narrowed to $2.9 million from $3.4 million in Q1 2024, reflecting cost controls and improved operating efficiencies.

• Improved operating cash burn by 43% and raised $3.8 million from warrant exercises.

• Expanded distribution through exclusive partnerships with NSM and Bionic P&O, entering new markets for personal health products.

Financial highlights

• Revenue: $3.4 million (down 10% year-over-year).

• Gross profit: $1.8 million (down 7% year-over-year).

• Gross margin: 54% (up from 52% in Q1 2024).

• Net loss: $2.9 million (improved from $3.4 million loss in Q1 2024).

• Cash and restricted cash: $8.1 million as of March 31, 2025.

Outlook and guidance

• Management expects operating losses and negative cash flows to continue, with current unrestricted cash projected to fund operations into Q4 2025.

• The company is seeking additional financing and may delay or abandon certain projects if funding is not secured.

• Majority of 2025 revenue expected from Enterprise Health sales, with Personal Health growth dependent on CMS reimbursement process improvements and new distribution partnerships.

• Management remains focused on executing growth strategy and expanding market reach.